← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
retifanlimab
L01FF10
Forms & Strengths
- injection 500 mg/20 mL (25 mg/mL) solution
- single-dose vials for intravenous use
Adult Dosing
- loading dose: 1000 mg on Day 1
- maintenance dose: 500 mg every 4 weeks
Pediatric Dosing
- safety and efficacy not established
- use not recommended
Indications
- metastatic or recurrent non-small cell lung cancer (NSCLC)
- locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC)
Mechanism of Action
- programmed death receptor-1 (PD-1) inhibitor
- enhances T-cell mediated immune response against tumor cells
Contraindications
- none
- warnings for: immune-mediated adverse reactions
Adverse Reactions
- fatigue
- musculoskeletal pain
- decreased appetite
- nausea
- diarrhea
- pruritus
- rash
- immune-mediated reactions
Drug Interactions
- moderate or severe hepatic impairment may increase toxicity
- avoid concurrent use of immunosuppressants
Curated Content: Needs Vetting Before Put to Clinical Use